Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 13/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407447 | 1.00 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL1481686 | 0.86 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL1786507 | 0.78 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL3427248 | 0.78 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL78044 | 0.76 | DRD4 (0.51) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL8924483 | 0.76 | DRD4 (0.51) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL9432019 | 0.74 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL6978725 | 0.73 | GFER (0.44) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL18689815 | 0.73 | HRH1 (0.43) | SLC6A2SLC6A4SLC6A3HTR2AADRB2 | |
| SCHEMBL21254392 | 0.73 | DRD4 (0.52) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637492-B2 | Benzothiazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-05-02 | — | — | US | disclosed |
| US-20150225407-A1 | Benzothiazole Kinase Inhibitors and Methods of Use | INTELLIKINE LLC | 2015-08-13 | — | — | US | disclosed |
| US-8993580-B2 | Benzothiazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | MTOR, PDPK1, PIKFYVE | SLC6A2 3880/4885SLC6A4 2424/4885SLC6A3 2854/4885 |
| US-20150225407-A1 | Benzothiazole Kinase Inhibitors and Methods of Use | MTOR, PDPK1, PIKFYVE | SLC6A2 3880/4885SLC6A4 2424/4885SLC6A3 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.